Compare Citius Pharmaceuticals Inc (CTXR) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Walmart Stores Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Walmart Stores Inc trades at $112.71 (market cap $904.83B). The key difference: Walmart Stores Inc is far larger — about 61805.3× Citius Pharmaceuticals Inc's market cap, and Walmart Stores Inc pays a 0.87% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | WMT | |
|---|---|---|
Market Cap | $14.64M | $904.83B |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $134.20 |
52-Week Low | $0.53 | $95.05 |
Enterprise Value | $10.86M | $968.28B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Walmart (WMT) trades at $114.78, up 0.77% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong revenue growth to $681.0B in 2025 and a rising net income margin of 2.85%. Analyst consensus is strongly bullish with a $142.10 price target, though technical indicators show resistance near $115. Recent news highlights operational expansions in drone delivery and AI tools, alongside competitive pressures as Amazon overtakes it on the Fortune 500.
The outlook for WMT is positive based on fundamental strength and analyst optimism, but near-term technical resistance and competitive risks warrant caution. Investment opportunity lies in its consistent earnings performance and dividend yield, while risks include market volatility and execution challenges in e-commerce growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
